M. Provencio Pulla

318P AI-driven dynamic prediction of prognosis in mNSCLC using CT scans and multimodal real-world data

T. Colin, J. Cadranel, S. Couraud, M. Provencio Pulla et autres

Clinical guidance remains limited for managing metastatic non-small cell lung cancer (mNSCLC) patients ineligible for targeted therapies. Usual biomarkers like RECIST criteria offer limited support to dynamically adapt treatment strategies after first-line initiation. Machine learning applied to routine multimodal data may help …

fr, es, ca, us (code pays fourni par la source)

1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study

M. Provencio Pulla, Lynne D. Berry, Melanie Quintana, Thomas William LeBlanc et autres

es, us, fr, Afrique du Sud (code pays fourni par la source)

LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

G.J. Riely, M-J. Ahn, Jade Clarke, Ibiayi Dagogo‐Jack et autres

us, kr, it, es, nl (code pays fourni par la source)

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Tina Cascone, Mark Magdi Awad, J.D. Spicer, Jie He et autres

us, ca, cn, jp, nl, cz, pl, fr, es (code pays fourni par la source)

932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816

E. Felip, C. Wang, T-E. Ciuleanu, G. Saylors et autres

es, cn, ro, jp, fr, us, gb, ca (code pays fourni par la source)